secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2025-11-19T23:59:59+00:00
Accession:  0001493152-25-024273
Event type: earnings
Sentiment:  negative
Materiality: 0.95
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk
--------------------------------------------------------------------------

- Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.
- Net loss $19.8M vs $2.4M in Q3 2024, driven by $18.6M impairment of in-process R&D due to market cap decline.
- Pre-tax loss $20.7M; R&D expense $0.4M (-16.3% YoY), G&A $1.7M (-5.1% YoY).
- Raised $2.05M in Q3 2025, $4.05M YTD; company flags need for equity/debt or collaboration funding.
- Lead programs: VAR 200 for FSGS (kidney) and IC 100 for cardiometabolic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/0001493152-25-024273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315225024273/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer